Free Republic

New Inhaled Insulin Drug Helps People With Diabetes PHILADELPHIA (CBS) — National Diabetes Month is observed every November so individuals, health care professionals, organizations, and communities across the country can bring attention to diabetes and its impact on millions of Americans. More than 400 million adults were living with diabetes in 2015 and this number is expected to increase to around 642 million or one in ten adults by 2040. One in two adults with diabetes is undiagnosed. Daniele Hargendader makes sure to stay fit as a personal trainer. She often works out in Pennypack Park. Daniele also has Type...

I can’t wait to get my next A1C test done (who says that?! but it’s true). I am now two-plus months into my use of new inhaled insulin Afrezza, and frankly I’m blown away by how well it performs (ooh, pun!) I’ve been hesitant to be too much of a cheerleader for Afrezza, because I thought maybe I was experiencing beginner’s luck – the thrill of any shiny new diabetes treatment can wear off pretty quickly – and given how controversial this drug is, I didn’t want to stir the pot unnecessarily. But sorry Naysayers, Afrezza is the bomb. At...

Hoping to appeal to millions of needle-phobic Americans with diabetes, drugmakers Sanofi and Mannkind have just launched Afrezza, an insulin that's inhaled, rather than injected. Afrezza was approved by the Food and Drug Administration last June for patients with either Type 1 or 2 diabetes, to be used along with other medicines, diet and exercise. Paris-based Sanofi SA, a major player in the huge diabetes treatment market, then licensed Afrezza's worldwide marketing rights from Mannkind Corp. of Valencia, California, which developed Afrezza.